Covid 19 Research using Clinical Trials (Home Page)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (2)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There are 2 clinical trials
Clinical Trials
Elderly, hypertension, diabetes and cardiovascular diseases are risk factors for COVID-19
morbility and mortality. However, the real reason for this is not yet understood. It is well
documented that gut microbiota has a critical role in health, particularly in the immune
system and therefore, we propose that gut microbiota composition could affect vulnerability
and disease outcomes of COVID-19.
NCT04355741 COVID-19 Other: Exposure
Primary Outcomes
Measure: Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity. Time: Stool samples of COVID-19 patients will be collected after subject enrollment (single point collection)
Secondary Outcomes
Measure: Differences in gut microbiota composition between COVID-19 patients in relation to mortality. Time: Through study completion, an average of 3 months.
Measure: Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals. Time: Through study completion, an average of 3 months.
Measure: Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation. Time: Through study completion, an average of 3 months.
Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and
cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have
a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to
investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19
outcome, particularly in hypertension and CV patients, proposing thus a personalized
therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.
NCT04370808 COVID-19 Other: Exposure
Primary Outcomes
Measure: Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity. Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity. Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).
Secondary Outcomes
Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to mortality. Time: Through study completion, an average of 3 months.
Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals. Time: Through study completion, an average of 3 months.
Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation. Time: Through study completion, an average of 3 months.
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality. Time: Through study completion, an average of 3 months.
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals. Time: Through study completion, an average of 1 year.
Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation. Time: Through study completion, an average of 3 months.
No related HPO nodes (Using clinical trials)